Metformin Use in Patients with Renal Dysfunction

Dosing Guidelines

The Kidney International guidelines recommend that metformin can be safely used in patients with eGFR ≥30 mL/min/1.73 m² with appropriate dose adjustments, but should be discontinued when eGFR falls below 30 mL/min/1.73 m² due to increased risk of lactic acidosis 1
For patients with eGFR ≥60 mL/min/1.73 m², standard dosing can be continued with no adjustment required, and renal function should be monitored at least annually 1, 2
For patients with eGFR 45-59 mL/min/1.73 m², dose reduction should be considered in patients with conditions that may increase risk of lactic acidosis, and renal function should be monitored every 3-6 months 1, 2
For patients with eGFR 30-44 mL/min/1.73 m², dose should be reduced to approximately 50% of maximum dose, and renal function should be monitored every 3-6 months 1, 2

The American Journal of Kidney Diseases recommends that metformin should be temporarily discontinued during situations that may increase risk of acute kidney injury, such as surgical procedures, iodinated contrast imaging studies, acute illness with risk of volume depletion, and hypoxic states 3
Patients on metformin for >4 years should have their vitamin B12 levels monitored, and patients should be educated about "sick day rules" - temporarily stopping metformin during acute illness 1, 2, 3

The American Journal of Kidney Diseases guidelines state that metformin has reduced mortality compared to other glucose-lowering therapies in patients with eGFR 30-60 mL/min/1.73 m², and has cardiovascular benefits, particularly in overweight patients with type 2 diabetes 3, 4
Metformin has a low risk of hypoglycemia compared to other agents, and does not cause weight gain 3

For patients with eGFR <30 mL/min/1.73 m² or those unable to tolerate metformin, alternative agents such as SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors can be considered, with appropriate dose adjustments and monitoring 1, 2, 5

For patients with eGFR 37 mL/min/1.73 m², the American College of Cardiology recommends reducing metformin to 50% of the maximum dose, typically 1000 mg daily, and monitoring renal function every 3-6 months 6
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest starting with 500 mg once daily with meals if initiating metformin therapy, or reducing the current dose by half if already on metformin, for patients with eGFR 30-44 mL/min/1.73 m² 6
Discontinue metformin immediately if eGFR falls below 30 mL/min/1.73 m² due to substantially increased risk of lactic acidosis, as recommended by the National Kidney Foundation 6

The American Diabetes Association recommends reducing sitagliptin to 25 mg once daily for patients with eGFR 30-44 mL/min/1.73 m², which is a 75% reduction from the standard dose of 100 mg daily 7
Sitagliptin can be safely used at this eGFR with appropriate dose adjustment, unlike metformin which is approaching its contraindication threshold, according to the European Association for the Study of Diabetes 6, 7

Consider transitioning to alternative agents, such as GLP-1 receptor agonists (dulaglutide, semaglutide, liraglutide), which require no dose adjustment at this eGFR and have cardiovascular benefits, as suggested by the American Heart Association 6
SGLT2 inhibitors can be used if eGFR >20-25 mL/min/1.73 m², depending on the specific agent, and provide cardiovascular and renal protection, according to the European Society of Cardiology 6